Malaria is a vector-borne disease that kills more people than AIDS. Although, there has been a decrease in the number of victims, it seems, in recent years, that malaria is prevalent on the African continent where a child dies from malaria every minute.
According to Marc Gentilini, General Delegate of the Fondation Chirac for the program Quality medicines and healthcare, anti-malarial medication is probably the most widely falsified drugs in Africa in recent decades. The distribution of these falsified drugs is seriously prejudicial to the poor who purchase them. Recent tests show that in 21 sub-Saharan countries, a third of malaria medication was found to be sub-standard according to chemical analyses, with an under-dosage of the active ingredient. In Africa, 20% of anti-malarial medication on the market is falsified.
The Fondation Chirac continues to mobilize political leaders to agree to implement legislative and normative tools like Medicrime, the Council of Europe’s Convention, to stop the manufacture and trafficking of counterfeit drugs by intervening at the level of these criminal actors.
President Jacques Chirac lobbied for the tax on air tickets (called the “Chirac tax”), which, through UNITAID, provides sustainable and reliable funding for the fight against malaria, as well as against HIV / AIDS and tuberculosis.
The French Academy of Medicine recently (March 2013) welcomed Martin Danis, who gave a paper emphasizing the need for a new drug strategy for severe cases of malaria through the use of intravenous artesunate in instead of traditional quinine, which has become ineffective in certain situations.
A malaria vaccine is regularly announced but today, on April 25, 2013, World Malaria Day, no operational vaccine is yet available. The most studied vaccine targets the pre-erythrocytic stages (its working name is RTS). Recently published results are disappointing. The protection for children varies between 30 and 50% and disappears three years after the vaccination. A vaccine against malaria is not for the immediate future.